

Richard J Perrin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4044554/publications.pdf>

Version: 2024-02-01

55
papers

2,464
citations

394421

19
h-index

254184

43
g-index

65
all docs

65
docs citations

65
times ranked

3948
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. <i>Nature</i> , 2009, 461, 916-922.	27.8	567
2	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	30.7	351
3	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	30.7	182
4	Meningeal lymphatics affect microglia responses and anti-A β immunotherapy. <i>Nature</i> , 2021, 593, 255-260.	27.8	179
5	Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e16032.	2.5	152
6	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 71.	6.2	131
7	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. <i>Nature Neuroscience</i> , 2021, 24, 1302-1312.	14.8	105
8	Neuropathologic assessment of participants in two multi-center longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). <i>Neuropathology</i> , 2015, 35, 390-400.	1.2	68
9	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. <i>Molecular Neurodegeneration</i> , 2019, 14, 18.	10.8	58
10	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 824-857.	0.8	56
11	The TMEM106B FTD-protective variant, rs1990621, is also associated with increased neuronal proportion. <i>Acta Neuropathologica</i> , 2020, 139, 45-61.	7.7	51
12	Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. <i>Oncotarget</i> , 2019, 8, e1561106.	4.6	50
13	Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation. <i>PLoS ONE</i> , 2013, 8, e64314.	2.5	47
14	Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. <i>Alzheimer's and Dementia</i> , 2015, 11, 815-822.	0.8	46
15	Widespread distribution of tauopathy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 72, 177-185.	3.1	42
16	Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 339-348.	2.4	35
17	Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain. <i>Acta Neuropathologica Communications</i> , 2020, 8, 149.	5.2	35
18	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 102-111.	1.7	35

#	ARTICLE	IF	CITATIONS
19	Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study. <i>Parkinson's Disease</i> , 2019, 2019, 1-12.	1.1	23
20	Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1423-1434.	3.7	22
21	Quantifying regional β -synuclein, amyloid β , and tau accumulation in lewy body dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 106-121.	3.7	21
22	Pituitary carcinoma: Two case reports and review of literature. <i>World Journal of Clinical Oncology</i> , 2020, 11, 91-102.	2.3	19
23	Genome-wide association study and functional validation implicates JADE1 in tauopathy. <i>Acta Neuropathologica</i> , 2022, 143, 33-53.	7.7	19
24	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102491.	2.7	17
25	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , 2021, 96, e1632-e1645.	1.1	16
26	Comparing amyloid- β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , 2021, 142, 689-706.	7.7	15
27	Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2022, 21, 118-131.	3.7	15
28	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , 2020, 16, 219-228.	0.8	13
29	Ante- and postmortem tau in autosomal dominant and late-onset Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2475-2480.	3.7	10
30	Stages of Objective Memory Impairment Predict Alzheimer's Disease Neuropathology: Comparison with the Clinical Dementia Rating's Sum of Boxes. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 185-195.	2.6	10
31	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. <i>Neurobiology of Aging</i> , 2021, 109, 43-51.	3.1	9
32	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	2.5	9
33	Protracted course progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2022, 29, 2220-2231.	3.3	8
34	Flortaucipir (tau) PET in LGI1 antibody encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 491-497.	3.7	7
35	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. <i>Neurobiology of Disease</i> , 2022, 168, 105714.	4.4	7
36	Polymer Coating Embolism: Cause of Cerebral Vasculopathy and Death following Congenital Heart Repair in Two Infants. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 978-980.	1.7	6

#	ARTICLE	IF	CITATIONS
37	The Free and Cued Selective Reminding Test Predicts Braak Stage. Journal of Alzheimer's Disease, 2021, 80, 175-183.	2.6	6
38	Calvarial Langerhans cell histiocytosis in an Adult: Typical imaging findings in an atypical age group. Radiology Case Reports, 2019, 14, 1478-1482.	0.6	5
39	A 66-Year-Old Woman with a Progressive, Longitudinally Extensive, Tract Specific, Myelopathy. Case Reports in Neurological Medicine, 2016, 2016, 1-9.	0.4	2
40	Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient. Journal of Neuroimmunology, 2021, 352, 577474.	2.3	2
41	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
42	A 71-Year-Old Man Presenting with Headache, Blurry Vision and Alexia without Agraphia. Brain Pathology, 2016, 26, 799-800.	4.1	1
43	P1-318: NEUROPATHOLOGIC HETEROGENEITY IN ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) SUBJECTS. , 2014, 10, P428-P428.		0
44	O3-14-03: Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease. , 2015, 11, P255-P255.		0
45	O4-02-01: Age-related neuropathology helps distinguish autosomal dominant from late-onset Alzheimer disease. , 2015, 11, P269-P269.		0
46	O3-04-03: Age-Related Neuropathology Helps Distinguish Autosomal Dominant from Late-Onset Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P291.	0.8	0
47	[ICP-180]: FLORTAUCIPIR TAU-PET SPECIFICITY IS MAINTAINED IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CREUTZFELDT-JAKOB DISEASE. Alzheimer's and Dementia, 2017, 13, P134.	0.8	0
48	[S3-01-02]: NEUROPATHOLOGIC HETEROGENEITY IN FAMILIAL AND LATE-ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P877.	0.8	0
49	P1-497: CLINICAL CORRELATES OF LEWY BODY PATHOLOGY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P520.	0.8	0
50	P2-087: EVALUATING NEUROIMMUNE IMAGING AS A BIOMARKER OF TISSUE CELLULARITY IN POSTMORTEM HUMAN BRAIN. Alzheimer's and Dementia, 2018, 14, P701.	0.8	0
51	ICP-062: EVALUATING NEUROIMMUNE IMAGING AS A BIOMARKER OF TISSUE CELLULARITY IN POSTMORTEM HUMAN BRAIN. Alzheimer's and Dementia, 2018, 14, P57.	0.8	0
52	Acquired mania associated with a left temporal meningioma. Bipolar Disorders, 2018, 20, 774-777.	1.9	0
53	ICP-166: TAU PET IMAGING IN LGI1 ENCEPHALITIS: DECIPHERING THE CONTRIBUTORS TO COGNITIVE IMPAIRMENT IN AUTOIMMUNE ENCEPHALITIS. Alzheimer's and Dementia, 2019, 15, P131.	0.8	0
54	ICP-046: CEREBRAL AMYLOID ANGIOPATHY IS MORE SEVERE IN AUTOSOMAL DOMINANT AD CASES WITH CEREBRAL MICROHEMORRHAGES: RESULTS FROM THE DIAN STUDY. Alzheimer's and Dementia, 2019, 15, P48.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Solitary Fibrous Tumor/Hemangiopericytoma Mimicking a Trigeminal Schwannoma: Case Report and Review of the Literature. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2018, 79, S1-S188.	0.8	0